Sigyn Therapeutics Inc. SIGY Archives

TuesdayMay 07, 2024 2:12 pm

QualityStocksNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces Publication of Article on Emerging Candidate – Sigyn Therapy(TM)

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced that it has published an article entitled: “Sigyn Therapy(TM), an Emerging Candidate to Address Endotoxemia, Sepsis and Drug-Resistant Viral & Bacterial Infections.” “When we designed Sigyn Therapy, we envisioned a medical device that could overcome the limitations of previous blood purification technologies to treat life-threatening conditions that are beyond the reach of drugs. Along with the efforts of our dedicated team, contributions from science advisors, collaborators and shareholders have helped to advance our vision toward reality,” said Jim Joyce, co-founder and CEO of Sigyn Therapeutics. “Consider that in the…

FridayApr 12, 2024 1:04 pm

QualityStocksNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Leveraging Portfolio to Overcome Current Limitations in Healthcare

Sigyn Therapeutics (OTCQB: SIGY), a medical technology that creates medical solutions to treat life-threatening conditions, is developing a portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM) and ImmunePrep(TM), which have each been designed to overcome a current limitation in healthcare. “As it relates to pathogen-associated disorders, the company has advanced Sigyn Therapy(TM) from concept through product development and subsequently completed five invitro blood purification studies, which validated the ability of Sigyn Therapy(TM) to extract 12 different therapeutic targets from human blood plasma. As a result of these study outcomes, Sigyn Therapy is a candidate to treat a wide range of…

MondayApr 01, 2024 9:00 am

Sigyn Therapeutics Inc. (SIGY) CEO Discusses Company’s Blood Purification Therapies to Address Cancer and Other Life-Threatening Conditions at the Emerging Growth Conference

Sigyn Therapeutics CEO Jim Joyce reviewed the company’s pipeline of technologies, including ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) to improve patient responses to various cancer therapies, and Sigyn Therapy(TM) to address drug resistant viral and bacterial infections, endotoxemia, and sepsis, a leading cause of hospital deaths in the United States The company created Sigyn Therapy(TM) to treat pathogen-associated disorders that are not addressed with drug therapies Sigyn Therapeutics is developing ChemoPrep(TM) and ImmunePrep(TM), to improve patient responses to chemotherapy and immunotherapeutic antibodies, respectively To reduce toxicity, the company designed ChemoPure(TM) to sweep off-target chemotherapy from the bloodstream before it is able to cause…

WednesdayMar 27, 2024 1:58 pm

QualityStocksNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Making Drugs Perform Better

Sigyn Therapeutics (OTCQB: SIGY), a medical technology company, is developing blood purification technologies to treat life-threatening conditions that are not addressed with current market-cleared drug agents as well as an expansive pipeline of technologies to optimize the benefit of cancer therapies. “The company’s lead product candidate, Sigyn Therapy(TM), is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (‘CRRT’) machines already installed in hospitals and clinics. The device incorporates a formulation of adsorbent components to optimize the broad-spectrum reduction of viral pathogens, bacterial toxins and inflammatory mediators from the bloodstream,” a…

WednesdayMar 20, 2024 12:27 pm

QualityStocksNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Developing Innovative Technologies to Address Critical Healthcare Challenges

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, recently expanded its therapeutic candidates, introducing ImmunePrep(TM) to improve the delivery of immunotherapeutic antibodies to treat cancer. “The company is also developing ChemoPrep(TM) and ChemoPure(TM) to optimize chemotherapy delivery and reduce treatment toxicity. The company further disclosed that clinical site locations for first-in-human studies for Sigyn Therapy(TM) have been identified. Sigyn Therapy(TM) is a novel blood purification technology to treat pathogen-associated conditions that are beyond the reach of drugs,” a recent article reads. “Sigyn Therapeutics is developing innovative medical technologies to address critical healthcare challenges. The company’s technologies show promise in…

FridayMar 15, 2024 1:08 pm

QualityStocksNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Filling Gap in Therapeutic Antibody Treatment Space

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, is currently focused on the development of four therapeutic candidates to address clearly defined limitations in global health. These include the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies to treat cancer, ChemoPrep(TM) to enhance the targeted delivery of chemotherapy, ChemoPure(TM) to reduce the toxicity of chemotherapy, and Sigyn Therapy(TM) to address pathogen-associated conditions that are beyond the reach of drugs. “Though highly valued, [immunotherapeutic antibodies to treat cancer] are limited by poor delivery to cancer cell targets and as a result, most patients do not respond to therapy. Inhibiting…

TuesdayMar 05, 2024 3:06 pm

QualityStocksNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces CEO Presentation at Upcoming Emerging Growth Conference

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, will be participating at tomorrow’s Emerging Growth Conference. The company announced that CEO Jim Joyce will give a live presentation; the presentation is slated to begin at 12 p.m. ET. According to the announcement, Joyce will provide an update on Sigyn Therapy(TM), the company’s novel blood-purification technology designed to address life-threatening conditions that are beyond the reach of drugs, and will review the company’s candidate products designed to enhance the benefit of chemotherapy and immunotherapeutic antibodies to treat cancer. The presentation will also include time for a Q&A. An archived copy…

TuesdayMar 05, 2024 9:45 am

Sigyn Therapeutics Inc. (SIGY) Therapeutic Candidates to Overcome Limitations in Healthcare

Sigyn Therapeutics is developing four medical device candidates – Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) – designed to overcome current therapeutic limitations in healthcare Sigyn Therapy(TM), the company’s lead product candidate, is a single-use disposable device to treat life-threatening inflammatory conditions that are beyond the reach of drugs ChemoPrep(TM) is designed to optimize the tumor-site delivery of chemotherapy, while ChemoPure(TM) intends to reduce the toxicity of chemotherapy by sweeping off-target chemotherapy out of the bloodstream ImmunePrep(TM) is designed to reduce the presence of circulating drug decoys that interfere with the delivery of immunotherapeutic antibodies to treat cancer Medical technology company…

FridayFeb 02, 2024 11:42 am

QualityStocksNewsBreaks – Sigyn Therapeutics Inc. (SIGY, SIGYD) Announces Implementation of a 1-for-40 Reverse Split

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, announced the completion of a 1-for-40 reverse split of its common stock. According to the announcement, the reverse split was implemented on Jan. 31, 2024. “As a result of the split, the company’s common stock will trade under the ticker symbol SIGYD for 20 business days and subsequently revert to trading under its historic symbol SIGY on Feb. 29, 2024,” the company stated in the press release. The company also reported that its post-split CUSIP number for its common stock is 82674U205. According to Sigyn Therapeutics, 1,221,043 of its common…

WednesdayJan 24, 2024 3:30 pm

QualityStocksNewsBreaks – Why Sigyn Therapeutics Inc. (SIGY) Is ‘One to Watch’

Sigyn Therapeutics (OTCQB: SIGY) is a development-stage medical technology company whose therapeutic candidates include Sigyn Therapy(TM), the ImmunePrep(TM) platform, ChemoPrep(TM), and ChemoPure(TM). “The company is advancing Sigyn Therapy to treat pathogen-associated inflammatory disorders that are not addressed with FDA-approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia, and sepsis, which is the leading cause of hospital deaths in the United States... In vitro studies have demonstrated the ability of Sigyn Therapy to eliminate life-threatening pathogen and inflammatory disease targets from human blood plasma… Sigyn designed the ImmunePrep platform to leverage the use of therapeutic antibodies…

Site Search

Company Search

Tag: Sigyn Therapeutics Inc. SIGY